TLC to Present Phase 3 Data of TLC599 in Late-Breaking Abstracts Session at ACR

Clinical benefits sustained to 24 weeks; second injection furthered benefits to 52 weeksSOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 08, 2023 (GLOBE NEWSWIRE) -- TLC BioSciences (TLC), a late clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical needs in orthopedic disorders, today announced that the Abstract Selection Committee of the American College of Rheumatology (ACR) has accepted TLC's late-breaking abstract on TLC599 for o

Related Keywords

Sydney ,New South Wales ,Australia ,Taiwan ,California ,United States ,San Diego Convention Center ,San Diego ,Taipei ,T Ai Pei ,David Hunter ,George Spencer ,Rheumatology At University Of Sydney ,Abstract Selection Committee ,American College ,Repeat Injection ,Cope Chair ,Western Ontario ,Mcmaster Universities Osteoarthritis Index ,George Spencer Green ,Chief Medical Officer ,Tlc ,Phase 3 Clinical Trials ,Cr ,Oral Presentation ,Placebo ,Pharmaceutical Company ,